Donate Help Contact The AHA Sign In Home
American Heart Association
Arteriosclerosis, Thrombosis, and Vascular Biology
Search: search_blue_button Advanced Search
Arteriosclerosis, Thrombosis, and Vascular Biology. 1997;17:963-968

This Article
Right arrow Full Text
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Frostegård, J.
Right arrow Articles by Schäfer-Elinder, L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Frostegård, J.
Right arrow Articles by Schäfer-Elinder, L.
(Arteriosclerosis, Thrombosis, and Vascular Biology. 1997;17:963-968.)
© 1997 American Heart Association, Inc.


Articles

Platelet-Activating Factor and Oxidized LDL Induce Immune Activation by a Common Mechanism

Johan Frostegård; Yi Hui Huang; Johan Rönnelid; ; Liselotte Schäfer-Elinder

From the Department of Medicine, Division of Rheumatology, Karolinska Hospital (J.F., Y.H.H., J.R.), and the Department of Physiological Chemistry, Karolinska Institute (L.S.-E.), Stockholm, Sweden.

Correspondence to Johan Frostegård, Department of Medicine, Division of Rheumatology, Karolinska Hospital, Karolinska Institute, S-17176 Stockholm, Sweden. E-mail johanf{at}rheum.ks.se

Abstract Platelet activating factor (PAF) is a phospholipid with proinflammatory and thrombogenic properties, which has been implicated in inflammatory disorders including vasculitis and asthma. PAF-like compounds are present in oxidized LDL (oxLDL), which has been detected in the atherosclerotic lesion, where it may activate monocytes, macrophages, and T cells. OxLDL may therefore both initiate and perpetuate inflammatory reactions in the artery wall. Herein we demonstrate that PAF has the capacity to induce enhanced interferon gamma (IFN-{gamma}) secretion in peripheral blood mononuclear leukocytes (PBMCs), as does oxLDL. Both oxLDL- and PAF-induced IFN-{gamma} secretions were inhibited by a specific PAF-receptor antagonist, WEB 2170. PAF-like lipids in oxLDL could thus be responsible for oxLDL-induced activation of immune-competent cells. The effects of PAF and oxLDL were inhibited by antibodies to major histocompatibility complex class II and thus depend on accessory cells like monocytes. Both PAF and oxLDL induced tumor necrosis factor-{alpha} (TNF-{alpha}) synthesis in peripheral blood. PAF-mediated TNF-{alpha} production was inhibited by WEB 2170, whereas oxLDL-induced TNF-{alpha} was only partially inhibited. These findings indicate that both PAF and oxLDL have the capacity to induce TNF-{alpha}, which may increase atherogenesis due to its pleiotropic proinflammatory effects. Our findings suggest that the PAF receptor plays an important role in the inflammatory component of atherosclerosis.


Key Words: platelet-activating factor • atherosclerosis • oxidized LDL • tumor necrosis factor • interferon gamma




This article has been cited by other articles:


Home page
Nephrol Dial TransplantHome page
J. J. Carrero, X. Hua, P. Stenvinkel, A. R. Qureshi, O. Heimburger, P. Barany, B. Lindholm, and J. Frostegard
Low levels of IgM antibodies against phosphorylcholine-A increase mortality risk in patients undergoing haemodialysis
Nephrol. Dial. Transplant., November 1, 2009; 24(11): 3454 - 3460.
[Abstract] [Full Text] [PDF]


Home page
Rheumatology (Oxford)Home page
J. Su, X. Hua, H. Concha, E. Svenungsson, A. Cederholm, and J. Frostegard
Natural antibodies against phosphorylcholine as potential protective factors in SLE
Rheumatology, August 1, 2008; 47(8): 1144 - 1150.
[Abstract] [Full Text] [PDF]


Home page
Physiol. Rev.Home page
A. Tedgui and Z. Mallat
Cytokines in Atherosclerosis: Pathogenic and Regulatory Pathways
Physiol Rev, April 1, 2006; 86(2): 515 - 581.
[Abstract] [Full Text] [PDF]


Home page
Arterioscler. Thromb. Vasc. Bio.Home page
J. Frostegard
Atherosclerosis in Patients With Autoimmune Disorders
Arterioscler Thromb Vasc Biol, September 1, 2005; 25(9): 1776 - 1785.
[Abstract] [Full Text] [PDF]


Home page
J. Lipid Res.Home page
P. Turunen, J. Jalkanen, T. Heikura, H. Puhakka, J. Karppi, K. Nyyssonen, and S. Yla-Herttuala
Adenovirus-mediated gene transfer of Lp-PLA2 reduces LDL degradation and foam cell formation in vitro
J. Lipid Res., September 1, 2004; 45(9): 1633 - 1639.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Respir. Cell Mol. Bio.Home page
J. B. Sedgwick, Y. S. Hwang, H. A. Gerbyshak, H. Kita, and W. W. Busse
Oxidized Low-Density Lipoprotein Activates Migration and Degranulation of Human Granulocytes
Am. J. Respir. Cell Mol. Biol., December 1, 2003; 29(6): 702 - 709.
[Abstract] [Full Text] [PDF]


Home page
Physiol. Rev.Home page
B. OSTERUD and E. BJORKLID
Role of Monocytes in Atherogenesis
Physiol Rev, October 1, 2003; 83(4): 1069 - 1112.
[Abstract] [Full Text] [PDF]


Home page
LupusHome page
E Svenungsson, G-Z Fei, K Jensen-Urstad, U de Faire, A Hamsten, and J Frostegard
TNF-{alpha}: a link between hypertriglyceridaemia and inflammation in SLE patients with cardiovascular disease
Lupus, June 1, 2003; 12(6): 454 - 461.
[Abstract] [PDF]


Home page
CirculationHome page
K. Y. Stokes, E. C. Clanton, K. P. Clements, and D. N. Granger
Role of Interferon-{gamma} in Hypercholesterolemia-Induced Leukocyte-Endothelial Cell Adhesion
Circulation, April 29, 2003; 107(16): 2140 - 2145.
[Abstract] [Full Text] [PDF]


Home page
Arterioscler. Thromb. Vasc. Bio.Home page
S. M. Prescott, T. M. McIntyre, G. A. Zimmerman, and D. M. Stafforini
Sol Sherry Lecture in Thrombosis: Molecular Events in Acute Inflammation
Arterioscler Thromb Vasc Biol, May 1, 2002; 22(5): 727 - 733.
[Abstract] [Full Text] [PDF]


Home page
Arterioscler. Thromb. Vasc. Bio.Home page
G. K. Hansson
Immune Mechanisms in Atherosclerosis
Arterioscler Thromb Vasc Biol, December 1, 2001; 21(12): 1876 - 1890.
[Abstract] [Full Text] [PDF]


Home page
HypertensionHome page
R. Wu, C. Lemne, U. de Faire, and J. Frostegard
Antibodies to Lysophosphatidylcholine Are Decreased in Borderline Hypertension
Hypertension, January 1, 2001; 37(1): 154 - 159.
[Abstract] [Full Text] [PDF]


Home page
J. Lipid Res.Home page
P. M. Morganelli, S. M. Kennedy, and T. I. Mitchell
Differential effects of interferon-{gamma} on metabolism of lipoprotein immune complexes mediated by specific human macrophage Fc{gamma} receptors
J. Lipid Res., March 1, 2000; 41(3): 405 - 415.
[Abstract] [Full Text]


Home page
J. Biol. Chem.Home page
M. Y. Chang, S. Potter-Perigo, C. Tsoi, A. Chait, and T. N. Wight
Oxidized Low Density Lipoproteins Regulate Synthesis of Monkey Aortic Smooth Muscle Cell Proteoglycans That Have Enhanced Native Low Density Lipoprotein Binding Properties
J. Biol. Chem., February 18, 2000; 275(7): 4766 - 4773.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
T. M. McIntyre, G. A. Zimmerman, and S. M. Prescott
Biologically Active Oxidized Phospholipids
J. Biol. Chem., September 3, 1999; 274(36): 25189 - 25192.
[Full Text] [PDF]


Home page
HypertensionHome page
R. Wu, U. de Faire, C. Lemne, J. L. Witztum, and J. Frostegard
Autoantibodies to OxLDL Are Decreased in Individuals With Borderline Hypertension
Hypertension, January 1, 1999; 33(1): 53 - 59.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
J. Frostegard, R. Wu, C. Gillis-Haegerstrand, C. Lemne, and U. de Faire
Antibodies to Endothelial Cells in Borderline Hypertension
Circulation, September 15, 1998; 98(11): 1092 - 1098.
[Abstract] [Full Text] [PDF]